Vertex Pharmaceuticals Incorporated (VRTX)Healthcare | Biotechnology | Boston, United States | NasdaqGS
541.69 USD
-5.86
(-1.070%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 540.78 -0.91 (-0.915%) ⇩ (Aug. 28, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:44 a.m. EDT
The momentum here is undeniable. In just two weeks, the stock surged nearly 15%, climbing well above both its fifty-day and two-hundred-day moving averages. This aggressive price action is backed by a robust balance sheet and healthy growth metrics, though the recent year-over-year decline suggests some profit-taking pressure. The options flow confirms the bullish sentiment, with traders placing heavy call bets at resistance levels while using puts primarily for insurance. While the company does not pay a dividend, its cash-rich status and high return on equity make it a compelling core holding. The statistical forecast model is currently neutral, which often lags behind actual price moves, so the immediate technical setup outweighs the model's hesitation. This looks like a high-conviction entry for the near term, supported by a fundamentally strong business that has compounded value significantly over the last decade. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.070754 |
| AutoTheta | 0.075396 |
| AutoARIMA | 0.075828 |
| AutoETS | 0.075830 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 50% |
| H-stat | 2.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.228 |
| Excess Kurtosis | -0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.767 |
| Revenue per Share | 49.507 |
| Market Cap | 137,210,077,184 |
| Trailing P/E | 31.51 |
| Forward P/E | 24.63 |
| Beta | 0.31 |
| Profit Margins | 35.00% |
| Website | https://www.vrtx.com |
As of Aug. 22, 2026, 3:44 a.m. EDT: Speculators are positioning for upside with significant call open interest at 565 and 580 strikes, alongside volume spikes at 660 and 700 for later expirations. Put writers are establishing downside protection around 330 to 470, creating a wide range of support. Implied volatility remains moderate, suggesting the market prices this move as standard rather than speculative.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.36546135 |
| Address1 | 50 Northern Avenue |
| All Time High | 555.69 |
| All Time Low | 3.25 |
| Ask | 550.25 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,053,360 |
| Average Daily Volume3 Month | 1,512,254 |
| Average Volume | 1,512,254 |
| Average Volume10Days | 1,053,360 |
| Beta | 0.305 |
| Bid | 539.3 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 79.921 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 541.69 |
| Current Ratio | 3.185 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 549.57 |
| Day Low | 540.1 |
| Debt To Equity | 9.767 |
| Earnings Call Timestamp End | 1,785,789,000 |
| Earnings Call Timestamp Start | 1,785,789,000 |
| Earnings Growth | 0.08 |
| Earnings Quarterly Growth | 0.065 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | 5,100,499,968 |
| Ebitda Margins | 0.40521 |
| Enterprise To Ebitda | 25.767 |
| Enterprise To Revenue | 10.441 |
| Enterprise Value | 131,422,445,568 |
| Eps Current Year | 19.03728 |
| Eps Forward | 21.99736 |
| Eps Trailing Twelve Months | 17.19 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 498.8946 |
| Fifty Day Average Change | 42.79541 |
| Fifty Day Average Change Percent | 0.085780464 |
| Fifty Two Week Change Percent | 36.546135 |
| Fifty Two Week High | 555.69 |
| Fifty Two Week High Change | -14.0 |
| Fifty Two Week High Change Percent | -0.025193904 |
| Fifty Two Week Low | 374.17 |
| Fifty Two Week Low Change | 167.51999 |
| Fifty Two Week Low Change Percent | 0.4477109 |
| Fifty Two Week Range | 374.17 - 555.69 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 680,362,200,000 |
| Float Shares | 252,682,799 |
| Forward Eps | 21.99736 |
| Forward P E | 24.625227 |
| Free Cashflow | 2,627,887,616 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 6,400 |
| Fullday Change | -5.85999 |
| Fullday Change Percent | -1.07022 |
| Fullday Price | 540.775 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.54957 |
| Gross Profits | 6,917,600,256 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0021 |
| Held Percent Institutions | 0.98157 |
| Implied Shares Outstanding | 253,300,000 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.vrtx.com/finances.html |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 967,075,200 |
| Last Split Factor | 2:1 |
| Long Business Summary | Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. |
| Long Name | Vertex Pharmaceuticals Incorporated |
| Market | us_market |
| Market Cap | 137,210,077,184 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_36235 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 4,405,199,872 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 138,782,528,936 |
| Number Of Analyst Opinions | 25 |
| Open | 547.09 |
| Operating Cashflow | 4,292,900,096 |
| Operating Margins | 0.38055 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.91 |
| Phone | 617 341 6100 |
| Post Market Change | -0.914978 |
| Post Market Change Percent | -0.16891174 |
| Post Market Price | 540.775 |
| Post Market Time | 1,787,961,539 |
| Previous Close | 547.55 |
| Price Eps Current Year | 28.454172 |
| Price Hint | 2 |
| Price To Book | 6.777818 |
| Price To Sales Trailing12 Months | 10.900762 |
| Profit Margins | 0.34997 |
| Quick Ratio | 2.536 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.65517 |
| Region | US |
| Regular Market Change | -5.85999 |
| Regular Market Change Percent | -1.07022 |
| Regular Market Day High | 549.57 |
| Regular Market Day Low | 540.1 |
| Regular Market Day Range | 540.1 - 549.57 |
| Regular Market Open | 547.09 |
| Regular Market Previous Close | 547.55 |
| Regular Market Price | 541.69 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 886,790 |
| Return On Assets | 0.11926 |
| Return On Equity | 0.23542999 |
| Revenue Growth | 0.125 |
| Revenue Per Share | 49.507 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 253,300,000 |
| Shares Percent Shares Out | 0.0164 |
| Shares Short | 4,146,973 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,986,691 |
| Short Name | Vertex Pharmaceuticals Incorpor |
| Short Percent Of Float | 0.0185 |
| Short Ratio | 3.11 |
| Source Interval | 15 |
| State | MA |
| Symbol | VRTX |
| Target High Price | 672.0 |
| Target Low Price | 350.0 |
| Target Mean Price | 563.12 |
| Target Median Price | 570.0 |
| Total Cash | 7,852,400,128 |
| Total Cash Per Share | 30.981 |
| Total Debt | 1,977,600,000 |
| Total Revenue | 12,587,200,512 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 17.19 |
| Trailing P E | 31.511925 |
| Trailing Peg Ratio | 1.896 |
| Triggerable | 1 |
| Two Hundred Day Average | 462.6258 |
| Two Hundred Day Average Change | 79.06421 |
| Two Hundred Day Average Change Percent | 0.17090316 |
| Type Disp | Equity |
| Volume | 886,790 |
| Website | https://www.vrtx.com |
| Zip | 2,210 |